nosc newsletter2 vol1 ed2 jul 2012 (1)

8/11/2019 NOSC Newsletter2 Vol1 Ed2 Jul 2012 (1)

http://slidepdf.com/reader/full/nosc-newsletter2-vol1-ed2-jul-2012-1 1/8

NOSC Newsletter 2012 Jul; 1(2) www.behestandarou.com

NOSC on its evolutionary journey

The Neuro-Oncology Scientific Club (NOSC)

put forward its aims and started its journey

about a year ago. This budding self centered

club got strong support and received

passionate attitude from the neuro-oncology

experts in the field. Experts from brain

tumor allied disciplines who have the

shared aim of “ serving brain tumor patients

better”, decided to unite within this

interdisciplinary scientific club.

The vision and mission of NOSC has been

providing a common place to cement the

links between neuro-oncology related

specialties and strengthening cross

disciplinary partnership to further help

brain tumor patients’ care in Iran,

respectively. In NOSC, members share their

experience in brain tumor care and science

so that together find out how their brain

tumor patients’ survival and quality of life

may further improve.

NOSC also tries to cater the needs of young

scholars and specialists with brain tumor

interest such as radiation oncologists, hem-

oncologist, radiologists, neurologists,

pathologists, etc. through providing high

quality educational case studies, reports and

presentations during the interval (seasonal)

sessions.

Like the so far conducted meetings, theoutcome report of forthcoming sessions and

future communications will be composed

for submission for possible publication in

international peer reviewed journals.

Adding to the above NOSC will pursue its aim to:

1. Report interesting brain tumor cases ofeducational value (NOSC case studyperiodical)2. Acting as a provincial and later on,national guideline definition group for braintumor diagnosis, management and followup.3. Organizing patients’ awarenesscampaigns and support programs.

Each provincial NOSC comprises regular

members, lead faculty and a chairing panel.

Contents:

NOSC on its evolutionary journey

The second NOSC meet-up in Mashhad

NOSC’s International visibility and exposure

NOSC Case Study Periodical

Congress links and neuro-oncology event updates

NOSC and the national scientific societies support

BRAIN TUMOR




The panel leads the discussions flow, lead

faculty may be speakers and members share

ideas and contribute.

There has been two fruitful sessions in

Mashhad and one in Tehran so far.

The scientific report of the first two

meetings got published in the following peer

reviewed international journals:

Anvari K., et al. Towards the Real

Interdisciplinary Approach in Treating

Brain Tumors: Report from the Neuro-

Oncology Scientific Club opening meeting -

NOSC 2011-13 October- Mashhad, IR Iran

WMC ONCOLOGY2011;2(1):WMC002381

http://www.webmedcentral.com/wmcpdf/

Article_WMC002381.pdf

Haddad P., et al. Turning Interdisciplinary

Brain Tumor Science into Survival; Report

from the Neuro-Oncology Scientific Club

Opening Session- NOSC 2012 -19 January-

Tehran, IR Iran. Report and Opinion,

2012;4:(2):42-53http://www.sciencepub.net/report/report0402/

007_8292report0402_42_53.pdf

NOSC is grateful to see specialist from

brain tumor related deciplines who continue

to join and expand provincial forums in

Tehran, Mashhad, Isfahan, Shiraz and

Tabriz. They mean to make NOSC not only a

transparent interdisciplinary discussion

forum, but also a practical platform for“serving better, together!”

The second NOSC meet-up in Mashhad

The second Mashhad NOSC meet-up ( NOSC-2) was conducted on 19th April 2012, in Pardisan

hotel, Mashhad. There were around 50 attendees ( 84% of the invitees participated). During this

lively and active meeting, radiation oncologists together with others discussed applicable

clauses of ESMO and NCCN guidelines in their current practice for high grade glioma brain

tumor patients. Neurosurgeons actively participated and discussed with oncologists and others,the future strategies for brain tumor patients referral and bidirectional collaborations. Adding to

these, Neurologists put forward discussions on anticonvulsant prophylaxis and further.

Amongst panelist, there were pathology and radiology experts discussing with others the

relevant issues. Moreover, fundamentals of translational research on medical genetics in GBM

were argued and agreed upon.During this meeting the final draft of the provincial brain tumor

registry software( PBTR) as well as NOSC case study Periodical details were communicated.

Forthcoming Mashhad NOSC was proposed to be in early October 2012.




This meeting was again a leap forward to let NOSC’s plans turn into practice.

The outcome report of the 2nd Mashhad NOSC meeting ( NOSC-2) is now published in the

IJMCR ( International Journal of Medical and Clinical Research) under the contributors’ names.

IJMCR is a peer reviewed journal published by Bioinfo International (ranked 8 th worldwide by-

Index Copernicus )Source: http://journals.indexcopernicus.com/toprankpubl.php

IJMCR has obtained impact value (ICV) of 4.47 by Index Copernicus. This journal is currently

indexed with Index Copernicus, EBSCO, ProQuest, DOAJ, LWW, Ovid, Scopus and Chemical

Abstract Services. The CAB abstracts are available in Thomson Web of Knowledge- ISI.

Source1:http://journals.indexcopernicus.com/masterlist.php?name=Master&litera=I&start=420&skok=30

Source 2: http://www.bioinfo.in/index.php

Anvari K., et al. (2012) From Fundamental Brain Tumor Science to Interdisciplinary bedside

Care; the Outcome Report from the Neuro-Oncology Scientific Club Second meet-up (NOSC-

2), 19th April 2012, Mashhad, Iran. International Journal of Medical and Clinical Research,

ISSN:0976-5530 & E-ISSN:0976-5549, Volume 3, Issue 5, pp.-168-175.

To view the journal-issue front page please click:http://www.bioinfo.in/journalvolume.php?id=39&month=6&year=2012

To retrieve the full paper’s PDF please check:

http://www.bioinfo.in/uploadfiles/13415739563_5_2_IJMCR.pdf




International visibility and exposure

NOSC and the ISPNO 2012, Toronto, Canada

This was another remarkable achievement in making NOSC more visible and practical.Tehran NOSC’s first discussion forum report, got accepted as a poster abstract in the 15thISPNO congress, June 24-27 2012, Toronto, Ontario, Canada .Congress site: http://www.ispno2012.com/abstract

This meeting hosted oncologists, neurosurgeons, radiation oncologists, neurologists, nurses, basic researchers, neuro-pathologists, neuro-radiologists, endocrinologists, psychologists, social workers, rehabilitation specialist and other professionals involved in the care of patients withcentral nervous system tumors.This meeting was sponsored and conducted by SNO (The Society for NeouroOncology).Together with all other abstracts, this is now published in the journal of Neuro-Oncology,

under “Neuro-Oncology in developing countries “ section.Journal’s data:

Impact-factor:111 5.483 5-Yr impact factor: 6.043 | PubMed central

To view the abstract follow the below link:http://neuro-oncology.oxfordjournals.org/content/14/suppl_1/i106.abstract

Citation: Neuro Oncol (2012) 14 (suppl 1): i106-i110. doi: 10.1093/neuonc/nos094




NOSC- Brain tumor registry proposal abstract and the EANO ( European Association of Neuro-Oncology)

The 10th Congress of the European

Association of NeuroOncology, will be held

in September 6-9, 2012 in Marseille, France, we are pleased to inform all NOSC members

that NOSC’s proposal abstract entitled

‘Neuro-Oncology Scientific Club and the

Iranian Brain Tumor Registry’ (Control

Number 2012-A-5-EANO) is accepted as a

poster communication to be presented at

this meeting.

Congress link: www.eano2012.eu

This means that the idea and content of the

brain tumor registry software which has

already been developed is ratified by the

EANO scientific committee.

The first interesting case is shared by 3 experts from radiation oncology, radiology and

neurology field in Tehran. The case details are being composed for submission for

possible publication in a case study journal. We’d like to herewith invite NOSC

contributors to share their interesting brain tumor ( mainly high grade glioma) cases

with the editorial committee of NOSC case study periodical.

What’s new about the

“NOSC Case Study Periodical”




“NOSC case study Periodical” will be particularly interested to publish cases on the

followings:

- Newly diagnosed GBM

- Interdisciplinary success in management of complex cases

- Learning from errors

- Rare presentations- Unexpected outcome ( positive or negative) after chemoradiation with

Temozolomide

- Adverse events seen with various therapeutic regimens.

The received case details will be analyzed and documented as case reports for

submission for publication in peer reviewed journals under contributors’ names.

NOSC scientific service section and Behestan Darou’s medical division will be pleased to

render any assistance your paper requires for preparation and submission.

For further information about “NOSC Case Study Periodical” the authors’ guideline

kindly contact the editorial office:

02188774200 ext 1634

[email protected]

The PBTR software in its final format is in hand. This will be installed in selected centers

in Tehran and other main provinces as pilot. Possible deficiencies and neededamendments will be identified in its pilot phase and the software will be fine tuned for

final launch.

Congress links and neuro-oncology event updates

If you want to plan ahead for attendance in any of the cardinal neuro-oncology/oncology

conferences following links may be of help.

http://www.eortc.org/conferences-and-courses/eortc-eano-esmo-trends-central-nervous-system-malignancies

22-23 March 2013, Prague, Czech Republic

Provincial Brain Tumor Registry (PBTR)




http://congress.mums.ac.ir/uzyaci

NOSC is now being endorsed by and receiving patronage from

the national scientific societies

Recently it has been decided that a steering board comprising delegates from official national

scientific societies would define NOSC’s overall strategies and plan of action. This executive

decision was made once the scientific societies graciously showed their willingness to support

NOSC. The steering board members list is to be finalized, shortly. There will be 1-3 delegates

from each of the following societies. The first NOSC steering board meeting will be held in early

October 2012.

6-8 September 2012, Mashhad, Iran

http://www.ecco-org.eu/Conferences/ ESSO-32

SNO 17th Annual Scientific Meeting and

Education Day | 15-18 Nov. 2012

http://www.soc-neuro-onc.org/en/cev/76

Iranian Cancer AssociationIranian Association of Surgeons, Neurosurgery Branch

Iranian Society of Radiation Oncology

Cancer Research Network of Iran

Iranian society of pathology

Iranian Society of pediatric hematology and oncology

Iranian society of radiology




TEMODAL

Indication

TEMODAL (temozolomide) is indicated for the treatment of adult patients with newly diagnosed glioblastomamultiforme concomitantly with radiotherapy and then as maintenance treatment.

Selected Important Safety InformationTEMODAL is contraindicated in patients who have a history of hypersensitivity (such as urticaria, allergic reactionincluding anaphylaxis, toxic epidermal necrolysis, and Stevens-Johnson syndrome) to any of its components, or toDTIC.

Patients treated with TEMODAL may experience myelosuppression including prolonged pancytopenia, which mayresult in aplastic anemia, which in some cases has resulted in a fatal outcome. In some cases, exposure toconcomitant medications associated with aplastic anemia including carbamazepine, phenytoin, andsulfamethoxazole/trimethoprim complicates assessment. Geriatric patients and women have been shown in clinicaltrials to have a higher risk of developing myelosuppression. Cases of myelodysplastic syndrome and secondarymalignancies, including myeloid leukemia, have also been observed.

Prophylaxis against Pneumocystis carinii pneumonia is required for all patients receiving concomitantTEMODAL and radiotherapy for the 42-day regimen. There may be a higher occurrence of PCP whentemozolomide is administered during a longer dosing regimen. However, all patients receiving temozolomide,particularly patients receiving steroids, should be observed closely for the development of PCP regardless ofthe regimen.

TEMODAR can cause fetal harm when administered to a pregnant woman. In nursing women, a decision should bemade whether to discontinue nursing or to discontinue TEMODAL, taking into account the importance of the drug tothe mother. The safety and effectiveness of TEMODAL in children have not been established.

As bioequivalence between TEMODAL Capsules and TEMODAL for Injection has been established only whenTEMODAL for Injection was given over 90 minutes, infusion over a shorter or longer period of time may result insuboptimal dosing. Additionally, the possibility of an increase in infusion-related adverse reactions cannot be ruled out.

TEMODAL Capsules should not be opened or chewed. If capsules are accidentally opened or damaged, rigorousprecautions should be taken with the capsule contents to avoid inhalation or contact with the skin or mucousmembranes.

Caution should be exercised when administered to those with severe hepatic or renal impairment.

The adverse event profile was similar in patients <65 years of age and those > 65 years.

The most common adverse reactions in clinical studies in the Concomitant Phase (Radiotherapy + TEMODAL) and theMaintenance Phase (TEMODAL alone), respectively, were alopecia 69%, 55%; fatigue 54%, 61%; nausea 36%, 49%;vomiting 20%, 29%; anorexia 19%, 27%; headache 19%, 23%; rash 19%, 13%; constipation 18%, 22%; with thefollowing important adverse events also reported: convulsions 6%, 11% and thrombocytopenia 4%, 8%.

Of these adverse events, those grade > 3 in clinical studies in the Concomitant Phase (Radiotherapy + TEMODAL)and the Maintenance Phase (TEMODAL alone), respectively, were fatigue 7%, 9%; nausea 1%, 1%; vomiting <1%,2%; anorexia 1%, 1%; headache 2%, 4%; rash 1%, 1%; constipation 1%, 0%; convulsions 3%, 3%; thrombocytopenia3%, 4%.

When laboratory abnormalities and adverse events were combined, Grade 3 or 4 neutropenia occurred in 8% and

Grade 3 or 4 platelet abnormalities, including thrombocytopenic events, occurred in 14% of patients treated withtemozolomide.

Adverse reactions reported from intravenous formulation studies that were not reported in TEMODAL Capsule studieswere: pain, irritation, pruritus, warmth, swelling, and erythema at infusion site as well as the following adversereactions: petechiae and hematoma.

Before prescribing TEMODAL, please read the Prescribing Information.

Source: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000229/WC500035621.pdf

nosc newsletter2 vol1 ed2 jul 2012 (1)

Documents